MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
common stock
$14,046,430
Proceeds from
subscription receivable
$882,539
Proceeds from exercise of
warrants
$3,627
Net cash provided by
financing activities
$14,568,918
Canceled cashflow
$363,678
Net change in cash
and cash...
$739,636
Canceled cashflow
$13,829,282
Payments on notes payable
$297,553
Payments of deferred
offering costs
$64,082
Stock repurchased
during stock split...
$2,043
Accounts payable and
accrued expenses
$1,542,453
Prepaid expenses and
other current assets
-$302,799
Stock-based compensation
$187,728
Depreciation
$3,918
Loss (gain) on
disposal of fixed assets
-$2,559
Net cash used in
operating activities
-$13,811,107
Net cash used in
investing activities
-$18,175
Canceled cashflow
$2,039,457
Net loss
-$15,850,564
Purchase of property and
equipment
$18,175
Back
Back
Cash Flow
source: myfinsight.com
CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc. (CNSP)